Search research articles
Contact Us
Filters
Showing results (51-60 of 60) with videos related to
Page
of 6
Sort By:
You have reached the last page of results.
This site can display upto 60 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 11, 2021
Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer
A Bardia, S M Tolaney, K Punie, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 22, 2021
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
A Gennari, F André, C H Barrios, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 5, 2020
Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer
A G Waks, O Cohen, B Kochupurakkal, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 19, 2025
Tucatinib and trastuzumab emtansine for patients with previously treated HER2-positive locally advanced and metastatic breast cancer: primary analysis of the randomized phase III trial HER2CLIMB-02
S A Hurvitz, S Loi, J O'Shaughnessy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 3, 2023
ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer
P Tarantino, G Viale, M F Press, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 17, 2021
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study
N Harbeck, P Rastogi, M Martin, et al.
ESMO Open
|
January 20, 2026
Pathological complete response with neoadjuvant pembrolizumab and chemotherapy in non-metastatic triple-negative inflammatory breast cancer
F Lynce, C Valenza, S M Niman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 17, 2022
Oncology clinical trial disruption during the COVID-19 pandemic: a COVID-19 and cancer outcomes study
Z Bakouny, C Labaki, S Bhalla, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 11, 2023
Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer
G Villacampa, N M Tung, S Pernas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 20, 2026
SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer
A C Garrido-Castro, S E Kim, T Li, et al.
Page
of 6
Search research articles
Search
Showing results (51-60 of 60) with videos related to
Sort By:
Page
of 6
You have reached the last page of results.
This site can display upto 60 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 11, 2021
Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer
A Bardia, S M Tolaney, K Punie, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 22, 2021
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
A Gennari, F André, C H Barrios, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 5, 2020
Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer
A G Waks, O Cohen, B Kochupurakkal, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 19, 2025
Tucatinib and trastuzumab emtansine for patients with previously treated HER2-positive locally advanced and metastatic breast cancer: primary analysis of the randomized phase III trial HER2CLIMB-02
S A Hurvitz, S Loi, J O'Shaughnessy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 3, 2023
ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer
P Tarantino, G Viale, M F Press, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 17, 2021
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study
N Harbeck, P Rastogi, M Martin, et al.
ESMO Open
|
January 20, 2026
Pathological complete response with neoadjuvant pembrolizumab and chemotherapy in non-metastatic triple-negative inflammatory breast cancer
F Lynce, C Valenza, S M Niman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 17, 2022
Oncology clinical trial disruption during the COVID-19 pandemic: a COVID-19 and cancer outcomes study
Z Bakouny, C Labaki, S Bhalla, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 11, 2023
Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer
G Villacampa, N M Tung, S Pernas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 20, 2026
SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer
A C Garrido-Castro, S E Kim, T Li, et al.
Page
of 6